336 clinical trials
grid
list
download
| Body (indexed field) | Identifiant (ID) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 29330 | Annie Drowart | Skin | EORTC | EORTC-2139-MG - COLUMBUS-AD | Trial closed for recruitment | Adjuvant encorafenib & binimetinib vs. placebo in fully resected stage IIB/C BRAF V600E/K mutated melanoma: a randomized triple-blind phase III study in collaboration with the EORTC Melanoma Group | Annie.Drowart@hubruxelles.be | 3 | 3 | ||
| 28585 | 1st line - DLBCL, transformed, follicular NHL grade IIIb | Marie Maerevoet | Non-Hodgkin lymphoma | Lysarc | Epi-RCHOP | Trial open for recruitment | A Phase Ib-II Study of tazemetostat (EPZ-6438) in newly diagnosed Diffuse Large B Cell Lymphoma (DLBCL) or high risk Follicular Lymphoma (FL) patients treated by R-CHOP | marie.maerevoet@hubruxelles.be | 1/2 | 1 | |
| 29409 | Andrea Gombos | Breast | Novartis | EPIK-B5 | Trial open for recruitment | EPIK-B5: A Phase III, randomized, double-blind, placebocontrolled study of alpelisib (BYL719) in combination with fulvestrant for men and postmenopausal women with HRpositive, HER2-negative advanced breast cancer with a PIK3CA mutation, who progressed on or after aromatase inhibitor and a CDK4/6 inhibitor | accueil.oncologie@hubruxelles.be | 3 | 3 | ||
| 29003 | Laura Polastro | Ovary | Novartis | EPIK-O | Trial closed | A Phase III, multi-center, randomized (1:1), open-label, activecontrolled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agent cytotoxic chemotherapy, in participants with no germline BRCA mutation detected, platinum-resistant or refractory, high-grade serous ovarian cancer (EPIK-O / CBYL719K12301) | laura.polastro@hubruxelles.be | 3 | 3 | ||
| 22933 | *Histologically confirmed adenocarcinoma of the prostate *Prostate cancer progression documented by PSA according to the Prostate Cancer Working Group 2 (PCWG2) criteria or radiological progression according to RECIST, version 1.1 *Two or more bone meta |
Carlos Artigas Guix | prostate | Bayer | ERA-223 | Trial closed | A phase III randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with abiraterone acetate and prednisone/prednisolone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve subjects with bone predominant metastatic castration-resistant prostate cancer (CRPC) | carlos.artigas@hubruxelles.be | 3 | 3 | |
| 22688 | At least one prior platinum-based systemic regimen/ RET | Thierry Berghmans | NSCLC | IBCSG | ETOP 12-17 ALERT-lung | Trial closed | A single arm phase II trial evaluating the activity of alectinib for the treatment of pretreated RET-rearranged advanced NSCLC (ETOP 12-17 ALERT-lung) | 2 | 2 | ||
| 22729 | Progression or relapse with anti-PD1 or anti-PD-L1 and platinum-based chemotherapy for locally advanced or metastatic urothelial carcinoma. | Nieves Martinez Chanza | Ureters - bladder - urethra | Astellas | EV-301 | Trial closed for recruitment | An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) | nieves.martinez-chanza@hubruxelles.be | 3 | 3 | |
| 22798 | Relasped/refractory patient | Christiane Jungels | Multiple | Imcheck | EVICTION | Trial open for recruitment | A fist-in-human, two-part, open-label, clinical study to assess the safety, tolerability and activity of intravenous doses of ICT01 as monotherapy and in combination with an Immune Checkpoint Inhibitor, in patients with advanced-stage, relapsed/refractory cancer | christiane.jungels@hubruxelles.be | 1 | 1 | |
| 22627 | after standard therapy | Thierry Gil | Soft tissue | Epizyme | EZH-202 | Trial closed | A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma | thierry.gil@hubruxelles.be | 2 | 2 | |
| 22682 | Any line/ ER positive/ HER2 negative/ RECIST 1.1 | Philippe Aftimos | Breast | G1 Therapeutics | G1T48-01 | Trial closed | A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Ascending Doses of G1T48 Alone and in Combination with Palbociclib in Women with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer (G1T48-01) | philippe.aftimos@hubruxelles.be | 1 | 1 | |
| 22676 | 2nd line/ RECIST 1.1/ Biopsy | Thierry Gil | prostate | Janssen | Galahad | Trial closed | A phase 2 efficacy and safety study of Niraparib in men with metastatic castration-resistant prostate cancer and DNA repair anomalies. | thierry.gil@hubruxelles.be | 2 | 2 | |
| 28922 | Relapse or Refractory Diffuse Large B-cell Lymphoma CD20+ DLBCL, Failed previous HDT-ASCT or not eligible for HDT-ASCT. ECOG PS score 0-2 Acceptable renal and liver function Patient must have detectable disease by PET scan and by CT scan or MRI. |
Marie Maerevoet | Non-Hodgkin lymphoma | Genmab | GCT3013-05 | Trial closed | A Randomized, Open-Label, Phase 3 Trial of Epocoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma | marie.maerevoet@hubruxelles.be | 3 | 3 | |
| 28483 | Philippe Aftimos | Multiple | BSMO | Geneo | Trial closed | A study to examine the value of broad agnostic NGS panel testing versus reimbursed organ-directed NGS: a Belgian Precision study of the BSMO in collaboration with the Cancer Centre | philippe.aftimos@hubruxelles.be | 4 | 4 | ||
| 28727 | Ioannis Karfis | ITM Solucin GmbH | GEP-NET | Trial open for recruitment | A prospective, randomised, Controlled, Open-label, Multicentre phase III study to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somato-statin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET ; ITM-LET-01) | ioannis.karfis@hubruxelles.be | 3 | 3 |